Janssen Pharmaceutica NV: Janssen Announces Treatment with ERLEADA?(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
FOR EMEA PHARMACEUTICAL TRADE AND MEDICAL MEDIA ONLY NOT FOR DISTRIBUTION IN BENELUX, SWEDEN AND ITALY
Janssen Pharmaceutica NV (Janssen) announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of apalutamide plus androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) when compared to placebo plus ADT.
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11 9:30 PM-10:15 PM CET).
Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model
A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The
Journal of Nuclear Medicine. The results of the murine study indicate that radionuclide therapy promotes prostate cancer immunogenicity, provoking a cellular response that makes the tumors more receptive to immunotherapy.
Prostate cancer is generally viewed as an immunological cold cancer in which immunotherapies only have moderate success. Increasing prostate cancer immunogenicity with prostate-specific membrane antigen (PSMA) radionuclide therapy, however, might render immunotherapies more successful. In our research we sought to exploit this effect by combining radionuclide therapy with immunotherapy in a mouse model of prostate cancer.
Boxing: Heavyweight boxing great Leon Spinks who shocked Muhammed Ali dies
7 Feb, 2021 12:01 AM
Quick Read
Former heavyweight world champion Leon Spinks has passed away. Photo / Getty
NZ Herald
Former heavyweight champion Leon Spinks Jr. has died after battling prostate and other cancers. He was 67.
Spinks died Friday night, according to a release from a public relations firm. His wife, Brenda Glur Spinks, and a few close friends and other family members were by his side when he passed away.
Spinks won gold at the 1976 Montreal Olympics. But he rose in prominence when he beat Muhammed Ali for the heavyweight title in 1978.
February 5, 2021 Multiparametric MRI-targeted biopsy for clinically significant prostate cancer can yield detection rates similar to systematic transrectal ultrasound-guided (TRUS) biopsy, while potentially enabling over one-third of prostate biopsies to be avoided, according to research published online February 4 in
In a multicenter, prospective, and randomized phase III study called PRostate Evaluation for Clinically Important Disease: MRI vs. Standard Evaluation Procedures (PRECISE), a team of researchers from Canada found that providing targeted biopsies after a positive multiparametric MRI scan was noninferior to systematic TRUS biopsies for detecting prostate cancers with an International Society of Urological Pathology grade group (GG) of 2 or higher.